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Laboratory studies suggest adrenergic blockers may inhibit the proliferation and 
migration of cancer cells, but epidemiological evidence of their effect on cancer incidence 
has proved inconsistent. We therefore conducted a case-control study using the Clinical 
Practice Research Datalink to assess the effect of adrenergic blockers upon incidence 
of prostate, lung, bowel and breast cancer. 
Methods 
Amongst patients aged 18 years or older contributing at least 2 years of prospectively 
gathered data between 01/01/1987 – 31/12/2012, we selected incident cases of relevant 
cancers and controls, frequency matched 10:1 by age. Logistic regression was used to 
adjust effect estimates for age, sex, smoking, alcohol use, and a number of potentially 
confounding co-morbidities and co-prescriptions.  
Results 
18968 colorectal, 19082 lung, 21608 prostate and 29109 breast cancers were identified. 
We found no evidence of a protective effect of adrenergic blockade in lung and prostate 
cancer and found a slightly increased risk of colorectal and breast cancers in users. This 
was largely explained by the effects of confounding in a multivariate analyses with final 
OR estimates of lung, colorectal, breast and prostate cancer of 0.99, 95% CI [0.96-
1.04]1.14, [1.09 – 1.18]1.10, [1.06 – 1.14]1.01, [0.98-1.05] respectively for beta blocker 







We found no evidence to suggest that adrenergic blocker use prevents common cancers. 
Indeed, we found a slight increased risk of colorectal and breast cancer which may reflect 
residual confounding. 
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Progress in developing treatments for cancer remains slow thus alternative strategies for 
drug development such as repurposing previously approved drugs are being considered 
(Pasquier, Ciccolini et al. 2011). This strategy may reduce risks, costs and time required 
in drug development (Pasquier, Ciccolini et al. 2011). A specific example of this is the 
potential anti-neoplastic effects of aspirin with a near 50% reduction in cancer specific 
mortality from colorectal cancer recently shown in those starting aspirin after diagnosis 
(Chan, Ogino et al. 2009), which has already led to a randomised controlled trial (Ali, 
Toh et al. 2011).   
Laboratory studies of both beta- and alpha-blockers have shown that by blocking 
adrenergic signalling they inhibit both stimulation of growth and migratory activity of 
tumour cells by these neurotransmitters (Masur, Niggemann et al. 2001; Benning and 
Kyprianou 2002; Drell IV, Joseph et al. 2003; Foster, Yono et al. 2004; Lang, Drell IV et 
al. 2004; Palm, Lang et al. 2006; Sood, Bhatty et al. 2006; Hui, Fernando et al. 2008; Al-
Wadei, Al-Wadei et al. 2009; Sakamoto, Schwarze et al. 2011; Pasquier, Andre et al. 
2013). Furthermore beta blockade is of proven efficacy in the treatment of infantile 
haemangiomas (Fuchsmann, Quintal et al. 2011; Xu, Lv et al. 2012). 
These encouraging results have led to a number of epidemiological studies on β-blockers 
which have not shown a consistent beneficial effect in common cancers (González-
Pérez, Ronquist et al. 2004; Perron, Bairati et al. 2004; Ronquist, Rodríguez et al. 2004; 
Algazi, Plu-Bureau et al. 2006; Rodriguez, Jacobs et al. 2009; Friedman, Udaltsova et 
al. 2011; Hallas, Christensen et al. 2012; Jansen, Below et al. 2012). Few 
epidemiological studies have been undertaken in alpha blockers but what evidence there 
is, is inconsistent. (Friedman, Udaltsova et al. 2011; Hallas, Christensen et al. 2012). 
Limited sample sizes and inadequate adjustment for confounders in some studies have 





we conducted a case-control study using data from the Clinical Practice Research 
Datalink (CPRD) database, a large population healthcare database to allow adjustment 
for relevant confounding variables. We investigated the 4 most common cancers in the 
UK; colorectal, lung, breast and prostate cancer (Statistics 2012) since laboratory studies 
have shown evidence of an anti-tumourigenic effects of adrenergic blockers upon them 
(Schuller and Cole 1989; Masur, Niggemann et al. 2001; Drell IV, Joseph et al. 2003) 
and CPRD provided adequate power to investigate each.  Additionally, we have 
investigated the effect of differing doses and durations of adrenergic blocker use and the 
specificity of its effect by comparing results to those found with another class of agents 





Materials and Methods 
Setting 
The Clinical Practice Research Datalink (CPRD) contains anonymised computerised 
clinical information from over 600 general practices across the UK with the earliest 
records dating to 1987. These records include more than 11 million patients (Card, 
Siffledeen et al. 2014) making it the largest source of anonymised longitudinal data from 
primary care in the world (Khan, Harrison et al. 2010). Individual records include 
demographic information, clinical diagnoses, prescription and treatment details.  
Study Population 
We conducted a frequency matched case-control study of subjects during the period in 
which they contributed prospectively gathered data to CPRD from the period 01/01/1987 
– 31/12/2012 and occurring after the age of 18 and at least 2 years after they entered 
the dataset. Cases were defined by a first recorded medical diagnosis of lung, bowel, 
prostate or breast cancer in females. Controls were selected from contributing subjects 
with no recorded medical diagnosis of prostate, lung, bowel or breast cancer in their 
clinical record prior to a random date allocated (henceforth referred to as their pseudo-
diagnosis date) and frequency matched by 10 year age bands in a ratio of 10:1 for each 
malignancy separately. In addition we limited control selection for breast cancer to 
females and for prostate cancer to males.   
Exposure and covariates 
Subjects with two or more prescriptions for alpha or beta blocker use within the 2 year 
window prior to diagnosis or pseudo-diagnosis were considered exposed. We then 
considered dose by determining the mean dose across all exposed days for each 
subject, and then dividing by the maximum recommended daily dose (of the individual 





standardised doses across a combination of the cancers under study to split subjects 
into high dose, low dose and unexposed categories. 
Age and sex were considered a priori confounders. Other potential confounders 
considered include smoking, alcohol use, co-morbidity (using the Charlson comorbidity 
Index as a composite measure (Charlson, Pompei et al. 1987), prophylactic medications 
(NSAID, statin and aspirin use), hormone replacement therapy and potential indications 
for use of the medications studied including ischaemic heart disease (IHD), heart failure 
(HF), hypertension, history of diabetes and benign prostatic hyperplasia and/or 
prostatism. Medication use was defined as two or more prescriptions for the specific 
medication within the 2 year window prior to diagnosis or pseudo-diagnosis. Co-morbidity 
and indication for use of the drug were assessed as any recordings of the variable prior 
to the date of diagnosis or pseudo-diagnosis. Charlson Index was a composite score of 
comorbidities categorised into none, 1 and 2. Age was calculated at diagnosis or pseudo-
diagnosis date while BMI, smoking and alcohol were measured as the most recent 
recording of the variable prior to the diagnosis or pseudo-diagnosis date. Smoking status 
was categorised as non-smoker, current smoker, ex-smoker, missing; alcohol status as 
non-drinker, current drinker, problem-drinker and missing and BMI into 5 categories 
including missing. We created a missing category for all variables with missing data. 
Data Analysis 
We analysed data using logistic regression with univariable and subsequently 
multivariable analyses for each cancer under study with the resulting odds ratios and 
95% confidence intervals presented. Amongst the variables we extracted data for based 
on the plausibility of their confounding the relationship being studies, we determined 
potential confounders based on their association with the exposure and outcome and 
corroborated by similar studies conducted in this area. We built the multivariable model 





confounders one at a time from the model in increasing importance that do not change 
the estimate of the effect of the primary exposure by at least 10%. We did this until none 
of the variables retained in the model could be removed without altering the effect 
estimate of the model significantly. At the end of each step of fitting the model, we 
repeated this process but instead progressively added the confounders one at a time to 
the model in decreasing importance to determine if included confounders remain 
significant in the model and removed confounders become significant in the model. We 
did this until we had only significant confounders present in the model.  
Sensitivity Analysis 
We assessed the effect of duration of adrenergic blocker use within a 10 year window 
prior to diagnosis or pseudo-diagnosis in a subset of subjects with 10 years of 
prospectively gathered data. We assessed the number of years of exposure of a subject 
starting with their diagnosis or pseudo-diagnosis date and looking at prior exposure back 
in time until their earliest exposure within this 10 year window. Subjects were considered 
exposed for those years in which they had at least one relevant prescription, and 
continuous exposure was considered to occur for the number of consecutive years in 
which subjects were exposed counting backwards from the diagnosis or pseudo-
diagnosis date.  
Further Analysis 
 Finally we repeated all analyses substituting calcium channel blockers as the exposure. 






We identified 18968 cases of colorectal cancer (46% women), 19082 cases of lung 
cancer (42% women), 21608 cases of prostate cancer and 29109 cases of breast 
cancer. Supplementary table 1 shows the age distribution of cases and their age-
matched controls.  
 
Cancer cases were more likely to be current drinkers and had more comorbidities and 
hypertension than their respective controls (Table 1). In addition, Lung cancer cases had 
more current and ex-smokers and a higher level of aspirin and statin use than their 
controls. There were also a smaller proportion of missing data for smoking, alcohol and 
BMI cases compared to their respective controls for all cancers (Table 1). All other 
variables were similarly distributed in cases and controls. 
 
Cancer cases had more adrenergic blocker use than controls (Table 2).  Univariable 
analysis showed a significant positive association between both alpha and beta blocker 
exposure and all cancers. (Table 2) After adjustment for confounders we observed no 
effect of betablocker use on the risk of prostate cancer (OR: 1.01, 95% CI [0.98 – 1.05]) 
and lung cancer 0.99 [0.96 – 1.04]) and similarly no effect of alphablocker use on the 
risk of breast cancer 1.08 [1.00 – 1.17] and lung cancer 1.03 [0.97 – 1.09] compared to 
non-use. A weak positive association remained between betablocker use and colorectal 
cancer 1.14 [1.09 – 1.18] breast cancer 1.10 [1.06 – 1.14] and similarly between 
alphablocker use and colorectal cancer 1.13 [1.07 – 1.20]. (Table 2) 
For calcium channel blockers similar patterns of effect to betablockers were observed in 





1.14 [1.10 – 1.18]  a slight increased risk was observed with calcium blocker exposure. 
(Supplementary table 2) 
 
Analysis by dose  
We found no clear evidence of differences in cancer risk with variations in dose. Though 
point estimates did vary by dose, changes were small and confidence intervals 
overlapped. Further details of adrenergic blocker use by dose are shown below (Table 
3) 
Analysis of duration in those with prolonged data 
We found no significant effects on cancer risk from regular long-term adrenergic blocker 








In this large case-control study we found no effect of betablocker exposure in the 2 year 
period prior to cancer diagnosis on the risk of lung or prostate cancer and a slight 
increase on the risk of colorectal and breast cancer. Alphablocker exposure showed no 
effect on the risk of breast and prostate cancer and a slight increase in the risk of 
colorectal cancer. Analysis by dose and long term exposure showed no clear dose or 
temporal effect for adrenergic blocker use on cancer risk. 
Study strengths and limitations 
This study is from a large primary care database representative of the UK population 
(Herrett, Thomas et al. 2010) and as data collection within the CPRD is prospective, 
information bias due to recall will be minimised. In addition, we were able to adjust for a 
number of important confounders including alcohol status, smoking status, BMI, 
medication use and comorbidities.  
A major limitation is our inability to individually validate cancer diagnoses and a potential 
therefore for misclassification. However, given the previously demonstrated high levels 
of specificity for diagnoses in these data i.e 99% of neoplasms (Dregan, Moller et al. 
2012) we do not believe this will have greatly influenced our study.  
Our analyses confirm the presence of appreciable confounding in the relationships we 
have studied, but as we lack data on some potential confounders such as family history, 
diet and exercise it is likely that residual confounding will remain. 
Another potential limitation is missing data for confounding factors both by over the 
counter medication use (primarily NSAIDS and aspirin) and by lifestyle factors with a 
smaller proportion of missing data observed for smoking, alcohol and BMI cases 
compared to their respective control. It is likely that these data will not be missing at 





comorbidities or the frequency of physician visits. We have attempted to minimise this 
potential information bias by including missing as a separate category in the analysis for 
alcohol use, smoking and BMI. The potential for some information bias and likelihood of 
residual confounding remains however.  
Another potential bias is the possibility that those who are prescribed anti-hypertensives, 
due to their increased contact with health services, are more likely to have an early 
cancer diagnosed. This bias cannot be entirely overcome, but since the same 
mechanism might be expected to increase prescription of other drugs used for similar 
indications we analysed calcium channel blockers. The results of the effect of calcium 
blockers were similar to those of betablockers and as these have different mechanisms 
of action it is unlikely the results seen in betablocker use reflect the effect of the drug but 
instead suggests bias by healthcare seeking behaviour.  
Our primary analysis restricted the assessment of adrenergic blocker use to the 
presence of 2 prescriptions within 2 years. It is possible that these criteria did not 
adequately reflect exposure as we have no data on adherence to treatment and results 
could instead represent low dose of adrenergic drug use. We therefore analysed the 
dose of adrenergic blocker use. Since minimal effects were seen with varying dose, we 
do not think that these issues are likely to invalidate our primary analysis. 
Furthermore, it is possible that the time window of 2 years represents insufficiently 
prolonged exposure to see a therapeutic effect on the occurrence of cancer, and a longer 
exposure period may be required. We therefore examined the effect of a longer duration 
of exposure in a subset of subjects that had up to 10 years of data prior to diagnosis or 
pseudo diagnosis date. These results did not alter our effect estimates and as a result 
we believe that a longer duration of adrenergic blocker exposure does not have a greater 
effect on the risk of cancer.  





Previous studies have examined betablocker use and the incidence of colorectal 
(Friedman, Udaltsova et al. 2011; Jansen, Below et al. 2012) prostate (Perron, Bairati et 
al. 2004; Ronquist, Rodríguez et al. 2004; Rodriguez, Jacobs et al. 2009; Friedman, 
Udaltsova et al. 2011)  breast (González-Pérez, Ronquist et al. 2004; Fryzek, Poulsen 
et al. 2006; Friedman, Udaltsova et al. 2011) lung (Friedman, Udaltsova et al. 2011) and 
all cancers (Algazi, Plu-Bureau et al. 2006; Friedman, Udaltsova et al. 2011; Hallas, 
Christensen et al. 2012). 
Some studies such as the matched case-control studies by Perron et al, utilised large 
clinical databases (Perron, Bairati et al. 2004) showing a reduced incidence of prostate 
cancer on betablocker exposure 0.86 [0.77-0.96] but only adjusted for the confounding 
factors of age, sex, aspirin use and recent medical contacts which differed from the 
results of our study.  
 Other studies considered betablocker use and cancer risk in sub-group analyses only 
and it is likely that these studies were underpowered to detect significant effects 
(González-Pérez, Ronquist et al. 2004; Fryzek, Poulsen et al. 2006; Rodriguez, Jacobs 
et al. 2009).  For instance, a nested case-control study by Gonazalez-Perez et al on 
antihypertensive use and breast cancer risk (González-Pérez, Ronquist et al. 2004) 
started with 3708 cases and 20000 controls but to examine adrenergic blocker use, 
duration of use was split into current use, past and no use and this resulted in a 
population of cases and controls with very small numbers for some levels of drug 
exposure. Results showed no statistically significant difference in breast cancer 
incidence for those patients on beta and alpha blocker use and differ from the results of 
our study on betablocker use (González-Pérez, Ronquist et al. 2004). 
The most convincing evidence from large population based studies was a case-control 
study by Ronquist et al in 2004 (Ronquist, Rodríguez et al. 2004), conducted using the 
CPRD database. This examined 1013 cases of prostate cancer and 10000 controls with 





Results showed no statistically significant difference between beta blocker users and 
non-users with an odds ratio of 0.8 [0.6-1.0] for current use and 1.1 [0.9-1.4] for past use 
compared to non-use and for alpha blocker use an odds ratio of 3.6 [2.8-4.6] for current 
use and 1.1 [0.8-1.7] for past use compared to non-use. As we have used the same data 
source, though a larger and more recent version of it than in this study, it is reassuring 
that we find similar results. We have however expanded upon this study by including 
cancers of the breast, bowel and lung and within this investigated the dose and duration 
of use as well as the indication of use and can therefore provide more extensive 
information on the effect of adrenergic blocker exposure on the risk of cancer.  
 
Interpretation 
In this study we find no effect in some cancers or a weakly positive association of 
adrenergic blockade in others, contrary to what might be expected based on evidence 
from laboratory studies. It is possible that a higher concentration of adrenergic blockers 
than that prescribed for cardiovascular indications are needed to reproduce the pro-
apoptotic effects observed in these laboratory models. Also, several preclinical studies 
propose that downstream beta adrenergic effects are mediated mainly by the β2 or β3 
adrenergic receptors (E, M et al. 2006; Thaker, Han et al. 2006). As β1-selective beta 
blockers are more commonly prescribed for cardiovascular therapy, we were unable to 
look at the non-selective beta blocker subgroup for a beneficial effect.  However, results 
are not strongly significant in any cancer under study and it is possible that the slight 
increase in cancer risk observed in some cancers and the associated small effect sizes 
represent residual confounding due to the limited or lack of data on potential confounders 






To our knowledge, this is the most comprehensive study to date of the effect of alpha 
and beta blocker use on the incidence of common cancers in the UK.  We found no 
significant association between adrenergic blocker use and a reduced incidence of 
cancer and our finding of no consistent dose-response, temporal relationship or 
specificity of effect (compared to calcium channel blockers) mean we believe it more 
than likely that the slight increased risk observed in some cancers is as a result of 
residual confounding. However, an effect in specific beta blocker subgroups cannot be 
ruled out and further epidemiological research will require even larger epidemiological 
studies or pooled data to produce statistically robust results. This study using a large 
population database does not provide support for the hypothesis that adrenergic blocker 
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Table 1: Lifestyle factors and Indications for use of adrenergic blockers for cases and controls  
  Colorectalcancer Lungcancer Prostatecancer Breastcancer 
 Cases        Controls Cases        Controls Cases         Controls Cases         Controls 
 N=18968  N=189667 N=19082  N=190816 N=21608   N=215959 N=29109   N=291142 
Exposure % % P-value % % P-value % % P-value % % P-value 
Male              54.4  44.6   <0.001 57.9 45.0     <0.001       
Female          45.6  55.4  42.1 55.0        
Smoking status            
Non-
smoker 48.7 43.6  15.0 43.7  45.3 34.8  58.3 50.1  
Current 
smoker 14.4 13.9  <0.0001 40.7 13.8  <0.0001 12.8 15.0  <0.0001 16.3 15.7  <0.0001 
Ex-smoker 32.0 22.4  41.1 22.7  37.9 30.3  20.2 16.0  
missing 4.9 20.1  3.2 19.8  4.0 19.9  5.2 18.2  
Alcohol status            
Non-
drinker 14.6 14.2  15.6 14.4  10.0 9.2  17.3 17.7  
Current 
drinker 68.7 56.1  <0.0001 66.3 56.4  <0.0001 75.6 60.8  <0.0001 68.0 59.1  <0.0001 
Problem-
drinker 2.8 1.9  5.3 1.9  2.7 2.9  1.4 0.2  
missing 13.9 27.8  12.8 27.3  11.7 27.1  13.3 23.0  
BMI             
19-24 31.5 26.1  36.6 26.0  30.1 24.2  34.5 30.1  
25-29 33.6 27.5  29.3 28.2  41.4 32.1  28.9 23.9  
30-34 13.2 11.0  <0.0001 10.3 11.1  <0.0001 12.6 11.2  <0.0001 13.8 11.1  <0.0001 
>35 4.8 4.4  3.6 4.5  2.7 3.0  7.3 6.4  
<19 2.9 2.4  6.4 2.2  1.2 1.3  2.4 2.6  
missing 14.0 28.6  13.8 28.0  12.0 28.2  13.1 25.9  
Hypertension            
Yes 41.5 32.1  <0.001 38.7 33.0  <0.001 41.9 32.0  <0.001 31.9 24.9  <0.001 
IHD             
Yes 16.4 13.4  <0.001 21.9 13.5  <0.001 19.1 18.0  <0.001 7.5 6.7  <0.001 
Aspirin use            
Yes 26.8 21.4  <0.001 33.1 21.7  <0.001 30.2 25.7  <0.001 14.2 11.9  <0.001 
Statin use            
Yes 27.7 20.1  <0.001 31.5 21.0  <0.001 31.0 24.5  <0.001 16.4 13.1  <0.001 
Charlson Index            
0 42.2 57.8   27.1 57.3  46.3 54.5  59.8 68.8  
1 18.8 18.6  <0.0001 22.6 18.5  <0.0001 20.8 19.5  <0.0001 17.1 16.8  <0.0001 
2 39.0 23.6  50.3 24.2  32.9 26.0  23.1 14.4  
BPH     Yes 7.9 4.8  <0.001 7.8 4.9  <0.001 30.6 11.3  <0.001       






Table 2: Association of alpha and betablockers with cancer 
         Univariate Analysis Multivariable Analysis 
Cancer type 
Exposure 
status Cases Controls Odds ratio 95% CI Odds ratio 95% CI 
Betablocker use            
  n % n %  Lower Upper  Lower Upper 
Colorectal Cancera Unexposed 15,080 79.5 160,137 84.4 1   1   
 Exposed 3,888 20.5 29,530 15.6 1.398 1.347 1.451 1.137 1.094 1.181 
Lung Cancera Unexposed 15,551 81.5 160,076 83.9 1   1   
 Exposed 3,531 18.5 30,740 16.1 1.182 1.138 1.229 0.994 0.955 1.035 
Prostate Cancerb Unexposed 17,237 79.8 179,690 83.2 1   1   
 Exposed 4,371 20.2 36,269 16.8 1.256 1.213 1.301 1.013 0.978 1.050 
Breast Cancerb Unexposed 24,895 85.5 257,365 88.4 1   1   
 Exposed 4,214 14.5 33,777 11.6 1.290 1.246 1.335 1.097 1.059 1.137 
Alphablocker use            
Colorectal Cancera Unexposed 17,438 91.9 179,364 94.6 1   1   
 Exposed 1,530 8.1 10,303 5.4 1.527 1.444 1.615 1.129 1.067 1.196 
Lung Cancerc Unexposed 17,460 91.5 180,155 94.4 1   1   
 Exposed 1,622 8.5 10,661 5.6 1.570 1.487 1.658 1.028 0.970 1.090 
Breast Cancerd Unexposed 28,333 97.3 285,293 98.0 1   1   
  Exposed 776 2.7 5,849 2.0 1.336 1.238 1.441 1.080 0.999 1.167 
Abbreviations:  CI=confidence interval 
a Adjusted for gender, age and smoking  
b Adjusted for age and smoking    
c Adjusted for gender, age, smoking and Charlson’s score  






Table 3: Dose of alpha and betablocker exposurea 
        
    Multivariable Analysis   Multivariable Analysis   
Cancer type   β use OR 95% CI α use OR 95% CI 
Betablocker 








        
 Unexposed 175217 1   196802 1   
 Low 23248 1.14 1.09 1.19 6186 1.07 0.99 1.16 




        
 Unexposed 175627 1   197615 1   
 Low 23896 0.99 0.95 1.04 6516 0.96 0.88 1.04 




        
 Unexposed 282260 1   313626 1   
 Low 25816 1.08 1.03 1.13 5333 1.06 0.97 1.16 




        
 Unexposed 196927 1       
 Low 28756 1.02 0.98 1.06     
  High 11798 1.00 0.94 1.06         
a
Dose was missing for 0.04% of betablocker use for all cancers 
  Dose was missing for 0.002% of alphablocker use in colorectal and lung cancer and 0.0003% in breast 
cancer 
b Adjusted for gender, age and smoking  
c 

























 Table 4: Long-term betablocker and alphablocker exposure 
Betablocker use 
        Multivariable Analysis 
Cancer type Exposure Cases Controls Multivariable 95% CI 
Breast Cancer Unexposed 7,904 63,988 1   
 ≥10yr 536 3,512 1.101 1.000 1.211 
Colorectal Cancer Unexposed 5,211 41,318 1   
 ≥10yr 516 3,290 1.071 0.971 1.182 
Lung Cancer Unexposed 5,283 41,659 1   
 ≥10yr 449 3,456 0.860 0.771 0.959 
Prostate Cancer Unexposed 6,148 48,739 1   
  ≥10yr 602 3,955 1.011 0.924 1.107 
                         Alphablocker use       
Breast Cancer Unexposed 10,310 80,906 1   
 ≥10yr 44 218 1.390 1.003 1.925 
Colorectal Cancer Unexposed 6,617 51,888 1   
 ≥10yr 55 326 0.953 0.712 1.275 
Lung Cancer Unexposed 6,636 52,505 1   











Supplementary Table 1: Demographic characteristics of cancer cases and controls 
 Cases Controls  
Cancer             n        %         n   % 
Colorectal         
Total 18968  189667  
Age     
18-39 217 1.2 2,190 1.2 
40-49 756 4.0 7,571 4.0 
50-59 2,323 12.2 23,217 12.2 
60-69 4,722 24.9 47,190 24.9 
70-79 6,317 33.3 63,167 33.3 
80 and above 4,633 24.4 46,332 24.4 
Lung     
Total 19082   190816   
Age     
18-39 111 0.6 1,110 0.6 
40-49 483 2.5 4,842 2.5 
50-59 2,189 11.5 21,885 11.5 
60-69 5,093 26.7 50,959 26.7 
70-79 7,008 36.7 70,061 36.7 
80 and above 4,198 22.0 41,959 22.0 
Prostate     
Total 21608   215959   
Age     
18-39 19 0.1 190 0.1 
40-49 159 0.7 1,589 0.7 
50-59 2,022 9.4 20,225 9.4 
60-69 6,589 30.5 65,883 30.5 
70-79 8,246 38.2 82,328 38.1 
80 and above 4,573 21.1 45,744 21.2 
Breast*     
Total 29109   291142   
Age     
18-39 1,267 4.3 12,669 4.4 
40-49 4,305 14.8 43,069 14.8 
50-59 7,385 25.4 73,912 25.4 
60-69 7,262 24.9 72,598 24.9 
70-79 4,876 16.8 48,779 16.8 
80 and above 4,014 13.8 40,115 13.8 








Supplementary Table 2: Association of calcium channel blockers with cancer 
 











95% CI   
Odds 
ratio 
95% CI    
Calcium 
blocker use 
                     
          n  %        n  %         Lower Upper   Lower Upper  
Colorectal 
Cancer
a 15,230 80 161,169 85 1     1      
  3,738 20 28,498 15 1.388 1.336 1.442 1.107 1.065 1.151  
Lung 
Cancerb 
14,842 78 161,184 85 1     1      
  4,240 22 29,632 15 1.554 1.499 1.611 1.037 0.997 1.079  
Prostate 
Cancerc 
16,824 78 179,779 83 1     1      
  4,784 22 36,180 17 1.413 1.366 1.462 1.141 1.102 1.181  
Breast 
Cancerd 
25,423 87 261,863 90 1     1      
  3,686 13 29,279 10 1.297 1.25 1.345 1.073 1.03 1.118  
a Adjusted for gender, age and smoking          
b Adjusted for gender, age, smoking and 
charlsonscore         
c Adjusted for age and smoking          
d Adjusted for age and hypertension            
 
